iTeos Therapeutics, Inc.
NASDAQ:ITOS
16.7 (USD) • At close September 13, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
| Revenue
| 12.595 | 267.63 | 344.775 | 0 | 0 | 0 |
| Cost of Revenue
| 0.898 | 0.813 | 0.615 | 0.535 | 0.611 | 0.505 |
| Gross Profit
| 11.697 | 266.817 | 344.16 | -0.535 | -0.611 | -0.505 |
| Gross Profit Ratio
| 0.929 | 0.997 | 0.998 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 113.3 | 97.359 | 59.369 | 29.9 | 19.211 | 17.189 |
| General & Administrative Expenses
| 50.396 | 43.947 | 40.505 | 15.34 | 8.837 | 4.312 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 50.396 | 43.947 | 40.505 | 15.34 | 8.837 | 4.312 |
| Other Expenses
| 4.083 | -3.263 | -10.181 | -5.933 | -4.779 | -0.163 |
| Operating Expenses
| 157.482 | 138.043 | 89.693 | 39.307 | 23.269 | 17.817 |
| Operating Income
| -151.101 | 126.324 | 244.901 | -45.24 | -28.048 | -21.501 |
| Operating Income Ratio
| -11.997 | 0.472 | 0.71 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 4.083 | 22.412 | 11.563 | 7.15 | 5.713 | -0.163 |
| Income Before Tax
| -109.03 | 148.736 | 256.464 | -38.09 | -22.335 | -18.046 |
| Income Before Tax Ratio
| -8.657 | 0.556 | 0.744 | 0 | 0 | 0 |
| Income Tax Expense
| 3.612 | 52.084 | 41.943 | -0.057 | 0.119 | 0.011 |
| Net Income
| -112.642 | 96.652 | 214.521 | -38.033 | -22.454 | -18.057 |
| Net Income Ratio
| -8.943 | 0.361 | 0.622 | 0 | 0 | 0 |
| EPS
| -3.15 | 2.72 | 6.1 | -1.09 | -0.64 | -2.4 |
| EPS Diluted
| -3.15 | 2.56 | 5.68 | -1.09 | -0.64 | -2.4 |
| EBITDA
| -143.989 | 130.39 | 255.685 | -38.772 | -21.724 | -17.475 |
| EBITDA Ratio
| -11.432 | 0.487 | 0.742 | 0 | 0 | 0 |